Gary M. Reisfield

2.3k total citations
67 papers, 1.5k citations indexed

About

Gary M. Reisfield is a scholar working on Public Health, Environmental and Occupational Health, Pharmacology and Anesthesiology and Pain Medicine. According to data from OpenAlex, Gary M. Reisfield has authored 67 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Public Health, Environmental and Occupational Health, 20 papers in Pharmacology and 18 papers in Anesthesiology and Pain Medicine. Recurrent topics in Gary M. Reisfield's work include Opioid Use Disorder Treatment (24 papers), Pain Management and Opioid Use (16 papers) and Forensic Toxicology and Drug Analysis (14 papers). Gary M. Reisfield is often cited by papers focused on Opioid Use Disorder Treatment (24 papers), Pain Management and Opioid Use (16 papers) and Forensic Toxicology and Drug Analysis (14 papers). Gary M. Reisfield collaborates with scholars based in United States. Gary M. Reisfield's co-authors include George R. Wilson, Roger L. Bertholf, Bruce A. Goldberger, Fern J. Webb, Chris W. Chronister, Mark F. Munsell, Susannah Kish Wallace, Edward A. Ross, Robert L. DuPont and Ajay D. Wasan and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The American Journal of Medicine.

In The Last Decade

Gary M. Reisfield

66 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary M. Reisfield United States 20 603 330 321 266 238 67 1.5k
Bridin Murnion Australia 19 419 0.7× 157 0.5× 256 0.8× 664 2.5× 205 0.9× 65 1.7k
Joji Suzuki United States 20 775 1.3× 344 1.0× 199 0.6× 348 1.3× 213 0.9× 96 1.8k
Michael F. Weaver United States 27 657 1.1× 103 0.3× 183 0.6× 254 1.0× 118 0.5× 71 2.4k
Gavin Bart United States 20 797 1.3× 124 0.4× 213 0.7× 259 1.0× 320 1.3× 70 1.9k
Barth Wilsey United States 22 543 0.9× 120 0.4× 547 1.7× 1.0k 3.9× 333 1.4× 38 1.9k
Paul A. Nuzzo United States 24 686 1.1× 188 0.6× 287 0.9× 379 1.4× 164 0.7× 51 1.5k
Kirk E. Evoy United States 18 581 1.0× 92 0.3× 250 0.8× 161 0.6× 192 0.8× 48 1.2k
Edgar H. Adams United States 21 553 0.9× 151 0.5× 425 1.3× 326 1.2× 189 0.8× 32 1.4k
Amanda Roxburgh Australia 27 883 1.5× 444 1.3× 279 0.9× 372 1.4× 218 0.9× 68 2.1k
Lauren J. Tanz United States 17 944 1.6× 184 0.6× 206 0.6× 113 0.4× 662 2.8× 34 1.9k

Countries citing papers authored by Gary M. Reisfield

Since Specialization
Citations

This map shows the geographic impact of Gary M. Reisfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary M. Reisfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary M. Reisfield more than expected).

Fields of papers citing papers by Gary M. Reisfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary M. Reisfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary M. Reisfield. The network helps show where Gary M. Reisfield may publish in the future.

Co-authorship network of co-authors of Gary M. Reisfield

This figure shows the co-authorship network connecting the top 25 collaborators of Gary M. Reisfield. A scholar is included among the top collaborators of Gary M. Reisfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary M. Reisfield. Gary M. Reisfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhou, Lili, Sandipan Bhattacharjee, C. Kent Kwoh, et al.. (2021). Association Between Dual Trajectories of Opioid and Gabapentinoid Use and Healthcare Expenditures Among US Medicare Beneficiaries. Value in Health. 24(2). 196–205. 4 indexed citations
2.
Zhou, Lili, Sandipan Bhattacharjee, C. Kent Kwoh, et al.. (2020). Dual‐trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study. Addiction. 116(4). 819–830. 32 indexed citations
3.
Harden, R. Norman, Gary M. Reisfield, & Rollin M. Gallagher. (2020). Publishing Consensus Conference Proceedings: Can We Avoid Missed Opportunities While Effectively Managing Bias?. Pain Medicine. 21(4). 658–659. 2 indexed citations
4.
Cooke, Brian R., et al.. (2017). The Elusive Standard of Care.. PubMed. 45(3). 358–364. 8 indexed citations
5.
Bertholf, Roger L. & Gary M. Reisfield. (2017). Opioid Use Disorders, Medication-Assisted Treatment, and the Role of the Laboratory. Laboratory Medicine. 48(4). e57–e61. 2 indexed citations
6.
Bertholf, Roger L., Rohit Sharma, & Gary M. Reisfield. (2016). Predictive Value of Positive Drug Screening Results in an Urban Outpatient Population. Journal of Analytical Toxicology. 40(9). 726–731. 11 indexed citations
7.
Reisfield, Gary M.. (2015). Alcohol and Its Biomarkers: Clinical Aspects and Laboratory Determination. Laboratory Medicine. 46(3). e72–e73. 9 indexed citations
8.
Reisfield, Gary M., Bruce A. Goldberger, & Roger L. Bertholf. (2015). Choosing the right laboratory: A review of clinical and forensic toxicology services for urine drug testing in pain management. Journal of Opioid Management. 11(1). 37–44. 3 indexed citations
9.
Bertholf, Roger L., et al.. (2014). Sensitivity of an Opiate Immunoassay for Detecting Hydrocodone and Hydromorphone in Urine from a Clinical Population: Analysis of Subthreshold Results. Journal of Analytical Toxicology. 39(1). 24–28. 8 indexed citations
10.
Reisfield, Gary M. & Karen J. Maschke. (2013). Urine Drug Testing in Long-term Opioid Therapy. Clinical Journal of Pain. 30(8). 679–684. 6 indexed citations
11.
Reisfield, Gary M.. (2010). Medical Cannabis and Chronic Opioid Therapy. Journal of Pain & Palliative Care Pharmacotherapy. 24(4). 356–361. 9 indexed citations
12.
Reisfield, Gary M., et al.. (2010). Opioid Prescription Underfilling among Retail Pharmacies. Pain Medicine. 11(4). 586–590. 2 indexed citations
13.
Reisfield, Gary M., Ajay D. Wasan, & Robert N. Jamison. (2009). The Prevalence and Significance of Cannabis Use in Patients Prescribed Chronic Opioid Therapy: A Review of the Extant Literature. Pain Medicine. 10(8). 1434–1441. 55 indexed citations
14.
Reisfield, Gary M., et al.. (2009). Substance Use Disorders in the Palliative Care Patient #127. Journal of Palliative Medicine. 12(5). 475–476. 6 indexed citations
15.
Reisfield, Gary M. & George R. Wilson. (2007). Prognostication in Heart Failure #143. Journal of Palliative Medicine. 10(1). 245–246. 12 indexed citations
16.
Reisfield, Gary M. & George R. Wilson. (2007). Rational Use of Sublingual Opioids in Palliative Medicine. Journal of Palliative Medicine. 10(2). 465–475. 34 indexed citations
17.
Reisfield, Gary M. & George R. Wilson. (2006). L’ús de metàfores en el discurs oncològic. 89(1). 27–30. 1 indexed citations
18.
Reisfield, Gary M. & George R. Wilson. (2005). The metamorphosis of hydromorphone. Journal of Opioid Management. 1(3). 139–145. 3 indexed citations
19.
Reisfield, Gary M. & George R. Wilson. (2004). Use of Metaphor in the Discourse on Cancer. Journal of Clinical Oncology. 22(19). 4024–4027. 184 indexed citations
20.
Fishman, Scott M., et al.. (2000). Adherence Monitoring and Drug Surveillance in Chronic Opioid Therapy. Journal of Pain and Symptom Management. 20(4). 293–307. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bridin Murnion Breakdown of academic impact, for papers by Joji Suzuki Breakdown of academic impact, for papers by Michael F. Weaver Breakdown of academic impact, for papers by Gavin Bart Breakdown of academic impact, for papers by Barth Wilsey Breakdown of academic impact, for papers by Paul A. Nuzzo Breakdown of academic impact, for papers by Kirk E. Evoy Breakdown of academic impact, for papers by Edgar H. Adams Breakdown of academic impact, for papers by Amanda Roxburgh Breakdown of academic impact, for papers by Lauren J. Tanz
Rankless by CCL
2026